REN Stock Analysis: Relx | AS
Specialty Business Services | AS, Netherlands | Market Cap: 54.305m EUR | 12M Return: -22.4% | GB00B2B0DG97 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 31.1M
Warnings
No concerns identified
Tailwinds
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
RELX PLC is a UK-headquartered information services company, founded in 1903, that provides analytics and decision tools for professional and business customers across North America, Europe, and international markets. Originally known as Reed Elsevier PLC, it adopted the RELX name in July 2015. The business operates through four segments: Risk (risk analytics and commercial healthcare products), Scientific, Technical & Medical (scientific and medical data sets), Legal (legal, regulatory, and business information and analytics), and Exhibitions (digital and in-person event tools).
RELX operates a primarily B2B subscription and data analytics model serving regulated professional markets such as insurance, science, healthcare, and law, with the Exhibitions segment adding physical and virtual events to the portfolio. The company is classified under the Industrials sector within the Diversified Support Services sub-industry.
- Risk segment analytics subscriptions drive recurring revenue growth
- Exhibitions revenue rebounds as trade show activity normalizes globally
- Share buybacks and pricing power support margin expansion outlook
| Net Income: 2.26b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.19 > 0.02 and ΔFCF/TA 3.50 > 1.0 |
| NWC/Revenue: -36.74% < 20% (prev -31.89%; Δ -4.85% < -1%) |
| CFO/TA 0.20 > 3% & CFO 2.92b > Net Income 2.26b |
| Net Debt (8.74b) to EBITDA (4.03b): 2.17 < 3 |
| Current Ratio: 0.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.79b) vs 12m ago -6.05% < -2% |
| Gross Margin: 62.64% > 18% (prev 65.48%; Δ -2.84% > 0.5%) |
| Asset Turnover: 66.24% > 50% (prev 66.55%; Δ -0.31% > 0%) |
| Interest Coverage Ratio: 16.67 > 6 (EBIT TTM 3.13b / Interest Expense TTM 187.5m) |
| DSRI: 1.06 (Receivables 2.33b/2.16b, Revenue 9.70b/9.53b) |
| GMI: 1.05 (GM 65.48% / 62.64%) |
| AQI: 0.99 (AQ_t 0.79 / AQ_t-1 0.80) |
| SGI: 1.02 (Revenue 9.70b / 9.53b) |
| TATA: -0.04 (NI 2.26b - CFO 2.92b) / TA 14.9b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of August 28, 2026, the stock is trading at EUR 31.24 with a total of 698,131 shares traded. Over the past week, the price has changed by +2.83%, over one month by -0.12%, over three months by +11.32% and over the past year by -22.35%.
Current recommended Stop Loss: 29.80 (which is 4.6% or 1.5 ATR below the current price).
Relx has no consensus analysts rating.
Market Cap GBP = 46.5b (54.3b EUR * 0.8569 EUR.GBP)
P/E Trailing = 21.3562
P/E Forward = 17.8571
P/S = 5.587
P/B = 36.9715
P/EG = 1.3744
Revenue TTM = 9.70b GBP
EBIT TTM = 3.13b GBP
EBITDA TTM = 4.03b GBP
Long Term Debt = 5.63b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 2.33b GBP (from shortTermDebt, last quarter)
Debt = 8.95b GBP (from shortLongTermDebtTotal, last quarter) + Leases 97.0m
Net Debt = 8.74b GBP (calculated: Debt 8.95b - CCE 218.8m)
Enterprise Value = 55.3b GBP (46.5b + Debt 8.95b - CCE 218.8m)
Interest Coverage Ratio = 16.67 (Ebit TTM 3.13b / Interest Expense TTM 187.5m)
EV/FCF = 19.08x (Enterprise Value 55.3b / FCF TTM 2.90b)
FCF Yield = 5.24% (FCF TTM 2.90b / Enterprise Value 55.3b)
FCF Margin = 29.88% (FCF TTM 2.90b / Revenue TTM 9.70b)
Net Margin = 23.27% (Net Income TTM 2.26b / Revenue TTM 9.70b)
Gross Margin = 62.64% ((Revenue TTM 9.70b - Cost of Revenue TTM 3.62b) / Revenue TTM)
Gross Margin QoQ = 64.09% (prev 61.19%)
Tobins Q-Ratio = 3.70 (Enterprise Value 55.3b / Total Assets 14.9b)
Interest Expense / Debt = 2.09% (Interest Expense 187.5m / Debt 8.95b)
Taxrate = 23.95% (714.3m / 2.98b)
NOPAT = 2.38b (EBIT 3.13b * (1 - 23.95%))
Current Ratio = 0.45 (Total Current Assets 2.90b / Total Current Liabilities 6.46b)
Debt / Equity = 7.27 (Debt 8.95b / totalStockholderEquity, last quarter 1.23b)
Debt / EBITDA = 2.17 (Net Debt 8.74b / EBITDA 4.03b)
Debt / FCF = 3.02 (Net Debt 8.74b / FCF TTM 2.90b)
Total Stockholder Equity = 2.31b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.41% (Net Income 2.26b / Total Assets 14.9b)
RoE = 97.47% (Net Income TTM 2.26b / Total Stockholder Equity 2.31b)
RoCE = 39.34% (EBIT 3.13b / Capital Employed (Equity 2.31b + L.T.Debt 5.63b))
RoIC = 22.42% (NOPAT 2.38b / Invested Capital 10.6b)
WACC = 4.97% (E(46.5b)/V(55.5b) * Re(5.62%) + D(8.95b)/V(55.5b) * Rd(2.09%) * (1-Tc(0.24)))
Discount Rate = 5.62% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -93.42 | Cagr: -3.43%
[DCF] Terminal Value 77.97% ; FCFF base≈2.65b ; Y1≈3.04b ; Y5≈4.47b
[DCF] Fair Price = 33.59 (EV 67.2b - Net Debt 8.74b = Equity 58.5b / Shares 1.74b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.98 | Revenue CAGR: 2.23% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=1.68 | Chg30d=+1.49% | Revisions=+40% | GrowthEPS=+14.5% | GrowthRev=+5.1%
EPS next Year (2027-12-31): EPS=1.90 | Chg30d=+1.53% | Revisions=+40% | GrowthEPS=+12.6% | GrowthRev=+6.6%
[Analyst] Revisions Ratio: +57% (up=4, down=0)